Soliqua 100/33

Soliqua 100/33 is a prescription medication used in the treatment of type 2 diabetes. It is a combination of two active ingredients: insulin glargine, a long-acting insulin, and lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist.

Composition

Soliqua 100/33 is composed of 100 units/mL of insulin glargine and 33 mcg/mL of lixisenatide. The combination of these two active ingredients helps to control blood sugar levels in adults with type 2 diabetes. Insulin glargine works by replacing the insulin that is normally produced by the body, while lixisenatide slows down the emptying of the stomach and reduces the amount of glucose made by the liver.

Usage

Soliqua 100/33 is used along with diet and exercise to improve blood sugar control in adults with type 2 diabetes. It is not recommended for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

Side Effects

Common side effects of Soliqua 100/33 include low blood sugar (hypoglycemia), nausea, diarrhea, and allergic reactions. Severe, life-threatening allergic reactions can occur and require immediate medical attention.

Precautions

Before starting Soliqua 100/33, patients should inform their healthcare provider about all their medical conditions, including if they have liver or kidney problems, are pregnant or planning to become pregnant, or are breastfeeding or planning to breastfeed.

Interactions

Soliqua 100/33 may interact with other medications, including other antidiabetic drugs, beta-blockers, diuretics, and certain antidepressants. Patients should inform their healthcare provider about all the medications they are currently taking.

See Also

• Insulin glargine
• Lixisenatide
• Type 2 diabetes
• Diabetic ketoacidosis